US20150299813A1 - Methods for detecting pathogen in coldwater fish - Google Patents

Methods for detecting pathogen in coldwater fish Download PDF

Info

Publication number
US20150299813A1
US20150299813A1 US14/689,749 US201514689749A US2015299813A1 US 20150299813 A1 US20150299813 A1 US 20150299813A1 US 201514689749 A US201514689749 A US 201514689749A US 2015299813 A1 US2015299813 A1 US 2015299813A1
Authority
US
United States
Prior art keywords
seq
primer
sequence
oligonucleotide
pair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/689,749
Other languages
English (en)
Inventor
Tsun-Yung Kuo
Wang-Ju HSIEH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schweitzer Biotech Co Ltd
Original Assignee
Upstartdna Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upstartdna Co Ltd filed Critical Upstartdna Co Ltd
Priority to US14/689,749 priority Critical patent/US20150299813A1/en
Assigned to UpstartDNA Co. Ltd. reassignment UpstartDNA Co. Ltd. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Hsieh, Wang-Ju, KUO, TSUN-YUNG
Publication of US20150299813A1 publication Critical patent/US20150299813A1/en
Assigned to SCHWEITZER BIOTECH COMPANY LTD. reassignment SCHWEITZER BIOTECH COMPANY LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UpstartDNA Co. Ltd.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the invention relates to the field of methods and pairs of oligonucleotides for detecting pathogens in coldwater fish.
  • the invention shall be able to provide such diagnosis quickly and decentralized, as the coldwater aquaculture is normally spread out in remote costal areas.
  • the disclosure relates to a method for detecting a pathogen in coldwater fish, comprising providing a sample potentially containing one or more nucleotide sequences of a pathogen in a coldwater fish, providing an oligonucleotide primer pair defining the 5′ ends of two complementary strands of a double stranded target sequence on the one or more nucleotide sequences of the pathogen, providing a polymerase, blending the sample, the oligonucleotide primer pair, the polymerase, deoxyadenosine triphosphates (dATPs), deoxycytidine triphosphates (dCTPs), deoxyguanosine triphosphates (dGTPs), and deoxythymidine triphosphates (dTTPs) in a container to form a polymerase chain reaction (PCR) mixture, subjecting the PCR mixture to insulated isothermal polymerase chain reaction (iiPCR) by heating the bottom of the container at a fixed temperature to form
  • PCR
  • the PCR mixture further comprises an oligonucleotide probe having a sequence complementary to a segment of the double stranded target sequence, a fluorescer molecule attached to a first location on the oligonucleotide probe, and a quencher molecule attached to a second location on the oligonucleotide probe such that the quencher molecule substantially quenches the fluorescer molecule whenever the oligonucleotide probe is not hybridized to the segment of the double stranded target sequence and such that the fluorescer molecule is substantially unquenched whenever the oligonucleotide probe is hybridized to the segment of the double stranded target sequence.
  • the pathogen is Candidatus Branchiomonas cysticola
  • the oligonucleotide primer pair comprises a first primer having a sequence of SEQ ID NO: 1 and a second primer having a sequence of SEQ ID NO: 2.
  • the PCR mixture further comprises an oligonucleotide probe, which is a 13- to 25-base pair (bp) oligonucleotide between the 136th to 225th nucleotides of 16S ribosomal RNA gene of Candidatus Branchiomonas cysticola (GenBank accession No. JQ723599).
  • the oligonucleotide probe has a sequence of SEQ ID NO: 3.
  • the pathogen is Candidatus Branchiomonas cysticola
  • the oligonucleotide primer pair comprises a first primer having a sequence of SEQ ID NOs: 23, 25, or 27, and a second primer having a sequence of SEQ ID NOs: 24, 26, or 28.
  • the PCR mixture further comprises an oligonucleotide probe, which is a 13- to 25-bp oligonucleotide between the 968th to 1068th nucleotides of 16S ribosomal RNA gene of Candidatus Branchiomonas cysticola (GenBank accession No. JQ723599).
  • the oligonucleotide probe has a sequence of SEQ ID NO: 29.
  • the pathogen is piscine reovirus (PRV)
  • the oligonucleotide primer pair comprises a first primer having a sequence of SEQ ID NOs: 4, 30, 32, 33, or 35, and a second primer having a sequence of SEQ ID NOs: 5, 31, 34, or 36.
  • the PCR mixture further comprises an oligonucleotide probe, which is a 13- to 25-bp oligonucleotide between the 3178th to 3287th nucleotides of segment L1 gene of PRV (GenBank accession No. GU994013).
  • the oligonucleotide probe has a sequence of SEQ ID NOs: 6 or 37.
  • the pathogen is infectious pancreatic necrosis virus (IPNV)
  • the oligonucleotide primer pair comprises a first primer having a sequence of SEQ ID NO: 7 and a second primer having a sequence of SEQ ID NOs: 8 or 9.
  • the PCR mixture further comprises an oligonucleotide, which is a 13- to 25-bp oligonucleotide between the 432nd to 519th nucleotides of segment A gene of IPNV (GenBank accession No. AY379740).
  • the oligonucleotide probe has a sequence of SEQ ID NO: 10.
  • the pathogen is salmonid alphavirus (SAV)
  • the oligonucleotide primer pair comprises a first primer having a sequence selected from a group consisting of SEQ ID NOs: 11, 12, and 13, and a second primer having a sequence selected from a group consisting of SEQ ID NOs: 14, 15, and 16.
  • the PCR mixture further comprises an oligonucleotide probe, which is a 13- to 25-bp oligonucleotide between the 446th to 534th nucleotides of SAV complete genome (GenBank accession No. KC122926).
  • the oligonucleotide probe has a sequence of SEQ ID NO: 17.
  • the pathogen is infectious salmon anemia virus (ISAV)
  • the oligonucleotide primer pair comprises a first primer having a sequence of SEQ ID NO: 18 or SEQ ID NO: 19 and a second primer having a sequence of SEQ ID NO: 20 or SEQ ID NO: 21.
  • the PCR mixture further comprises an oligonucleotide probe, which is a 13- to 25-bp oligonucleotide between the 178th to 305th nucleotides of non-structural protein and matrix protein genes of ISAV (GenBank accession No. DQ785286).
  • the oligonucleotide probe has a sequence of SEQ ID NOs: 22 or 38.
  • the disclosure relates to a pair of oligonucleotides for detecting pathogens in coldwater fish.
  • the pathogen is Candidatus Branchiomonas cysticola
  • the pair of oligonucleotide comprises a first primer having a sequence of SEQ ID NO: 1 and a second primer having a sequence of SEQ ID NO: 2.
  • the pair of oligonucleotides further comprises an oligonucleotide probe having a 13- to 25-bp oligonucleotide between the 136th to 225th nucleotides of 16S ribosomal RNA gene of Candidatus Branchiomonas cysticola (GenBank accession No.
  • the oligonucleotide probe has a sequence of SEQ ID NO: 3.
  • the pathogen is Candidatus Branchiomonas cysticola
  • the pair of oligonucleotide comprises a first primer having a sequence of SEQ ID NOs: 23, 25, or 27, and a second primer having a sequence of SEQ ID NOs: 24, 26, or 28.
  • the pair of oligonucleotides further comprises an oligonucleotide probe having a 13- to 25-bp oligonucleotide between the 968th to 1068th nucleotides of 16S ribosomal RNA gene of Candidatus Branchiomonas cysticola (GenBank accession No.
  • the oligonucleotide probe has a sequence of SEQ ID NO: 29.
  • the pathogen is piscine reovirus (PRV)
  • the pair of oligonucleotides comprises a first primer having a sequence of SEQ ID NOs: 4, 30, 32, 33, or 35, and a second primer having a sequence of SEQ ID NOs: 5, 31, 34, or 36.
  • the pair of oligonucleotides further comprises an oligonucleotide probe having a 13- to 25-bp oligonucleotide between the 3178th to 3287th nucleotides of segment L1 gene of PRV (GenBank accession No.
  • the oligonucleotide probe has a sequence of SEQ ID NOs: 6 or 37.
  • the pathogen is infectious pancreatic necrosis virus (IPNV)
  • the pair of oligonucleotides comprises a first primer having a sequence of SEQ ID NO: 7 and a second primer having a sequence of SEQ ID NOs: 8 or 9.
  • the pair of oligonucleotides further comprises an oligonucleotide probe having a 13- to 25-bp oligonucleotide between the 432nd to 519th nucleotides of segment A gene of IPNV (GenBank accession No.
  • the oligonucleotide probe has a sequence of SEQ ID NO: 10.
  • the pathogen is salmonid alphavirus (SAV)
  • the pair of oligonucleotides comprises a first primer having a sequence selected from a group consisting of SEQ ID NOs: 11, 12, and 13, and a second primer having a sequence selected from a group consisting of SEQ ID NOs: 14, 15, and 16.
  • the pair of oligonucleotides further comprises an oligonucleotide probe having a 13- to 25-bp oligonucleotide between the 446th to 534th nucleotides of SAV complete genome (GenBank accession No.
  • the oligonucleotide probe has a sequence of SEQ ID NO: 17.
  • the pathogen is infectious salmon anemia virus (ISAV)
  • the pair of oligonucleotides comprises a first primer having a sequence of SEQ ID NOs: 18 or 19 and a second primer having a sequence of SEQ ID NOs: 20 or 21.
  • the pair of oligonucleotides further comprises an oligonucleotide probe having a 13- to 25-bp oligonucleotide between the 178th to 305th nucleotides of non-structural protein and matrix protein genes of ISAV (GenBank accession No.
  • the oligonucleotide probe has a sequence of SEQ ID NOs: 22 or 38.
  • FIG. 1A shows the results of conventional PCR test of Candidatus Branchiomonas cysticola with primers BCF1 and BCR1; lanes 1 to 11: results of conventional PCR performed with 10 10 10 9 , 10 8 , 10 7 , 10 6 , 10 5 , 10 4 , 10 3 , 10 2 , 10 1 , 10 0 copies of pUC57-BC plasmid respectively; lane 12: results of conventional PCR performed without DNA template (negative control).
  • FIG. 1A shows the results of conventional PCR test of Candidatus Branchiomonas cysticola with primers BCF1 and BCR1; lanes 1 to 11: results of conventional PCR performed with 10 10 10 9 , 10 8 , 10 7 , 10 6 , 10 5 , 10 4 , 10 3 , 10 2 , 10 1 , 10 0 copies of pUC57-BC plasmid respectively; lane 12: results of conventional PCR performed without DNA template (negative control).
  • FIG. 1A shows the results of
  • FIG. 1B shows the results of iiPCR test of primers BCF1 and BCR1 and probe BCP1; lane 1: result of iiPCR performed without DNA template (negative control); lanes 2 to 7: results of iiPCR performed with 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of pUC57-BC plasmid respectively.
  • FIG. 1B shows the results of iiPCR test of primers BCF1 and BCR1 and probe BCP1; lane 1: result of iiPCR performed without DNA template (negative control); lanes 2 to 7: results of iiPCR performed with 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of pUC57-BC plasmid respectively.
  • FIG. 1C shows the results of iiPCR test for specificity of primers BCF1 and BCR1 and probe BCP1; lane 1: result of iiPCR performed without DNA template (negative control); lanes 2 to 8: results of iiPCR performed with DNA/RNA template of salmon gill, SAV, IPNV, ISAV, NNV, PRV, and pUC57-BC plasmid.
  • FIG. 1C shows the results of iiPCR test for specificity of primers BCF1 and BCR1 and probe BCP1; lane 1: result of iiPCR performed without DNA template (negative control); lanes 2 to 8: results of iiPCR performed with DNA/RNA template of salmon gill, SAV, IPNV, ISAV, NNV, PRV, and pUC57-BC plasmid.
  • 1D shows the results of iiPCR test for different primers and probe BCP2; lanes 1 and 2: results of iiPCR performed with primers BCF2 and BCR2 and probe BCP2 without DNA template (lane 1, negative control) and with DNA template (lane 2); lanes 3 and 4: results of iiPCR performed with primers BCF3 and BCR3 and probe BCP2 without DNA template (lane 3, negative control) and with DNA template (lane 4); lanes 5 and 6: results of iiPCR performed with primers BCF4 and BCR4 and probe BCP2 without DNA template (lane 5, negative control) and with DNA template (lane 6).
  • FIG. 1D shows the results of iiPCR test for different primers and probe BCP2
  • lanes 1 and 2 results of iiPCR performed with primers BCF2 and BCR2 and probe BCP2 without DNA template (lane 1, negative control) and with DNA template (lane 2); lanes 3 and 4: results of iiPCR performed with primers BCF3 and BCR3 and probe BCP2
  • FIG. 1E shows the results of iiPCR test for sensitivity of primers BCF3, BCR3, and probe BCP2; lane 1: result of iiPCR performed without DNA template (negative control); lanes 2 to 8: results of iiPCR performed with 10°, 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of pUC57-BC plasmid respectively.
  • FIG. 1F shows the results of real-time PCR test of Candidatus Branchiomonas cysticola , pUC57-BC plasmid, with primers BCF3 and BCR3.
  • “M” represents molecular weight marker; arrows indicate the target PCR products; “+” indicates fluorescent signal was detected in the sample, and “ ⁇ ” indicates fluorescent signal was not detected in the sample.
  • FIG. 2A shows the results of conventional PCR test of piscine reovirus (PRV) with primers PRVF1 and PRVR1; lanes 1 to 6: results of conventional PCR performed with 10 6 , 10 5 , 10 4 , 10 3 , 10 2 , 10 1 copies of pUC57-PRV plasmid respectively; lane 7: results of conventional PCR performed without DNA template (negative control).
  • FIG. 2B shows the results of iiPCR test of primers PRVF1 and PRVR1 and probe PRVP1; lanes 1 and 3: results of iiPCR performed with pUC57-PRV; lanes 2 and 4: results of iiPCR performed without DNA template (negative controls).
  • FIG. 2A shows the results of conventional PCR test of piscine reovirus (PRV) with primers PRVF1 and PRVR1; lanes 1 to 6: results of conventional PCR performed with 10 6 , 10 5 , 10 4 , 10 3 , 10 2 , 10 1 copies of pUC57-PRV plasm
  • 2C shows the results of iiPCR test of different primers and probe PRVP1; lanes 1 and 3: results of iiPCR performed with primers PRVF2, PRVR2 and probe PRVP1, and without DNA template (negative controls); lanes 2 and 4: results of iiPCR performed with primers PRVF2, PRVR2 and probe PRVP1, and with pUC57-PRV; lanes 5 and 7: results of iiPCR performed with primers PRVF3, PRVR2 and probe PRVP1, and without DNA template (negative controls); lanes 6 and 8: results of iiPCR performed with primers PRVF3, PRVR2 and probe PRVP1, and with pUC57-PRV; lanes 9 and 11: results of iiPCR performed with primers PRVF4, PRVR4 and probe PRVP1, and without DNA template (negative controls); lanes 10 and 12: results of iiPCR performed with primers PRVF4, PRVR4 and probe PRVP1, and with pUC57-PRV.
  • FIG. 2D shows the results of iiPCR test for sensitivity of primers PRVF2, PRVR2, and probe PRVP1; lane 1: result of iiPCR performed without DNA template (negative control); lanes 2 to 7: results of iiPCR performed with 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of in vitro transcriptional RNA of PRV respectively.
  • FIG. 2D shows the results of iiPCR test for sensitivity of primers PRVF2, PRVR2, and probe PRVP1; lane 1: result of iiPCR performed without DNA template (negative control); lanes 2 to 7: results of iiPCR performed with 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of in vitro transcriptional RNA of PRV respectively.
  • 2E shows the results of iiPCR test for sensitivity of primers PRVF3, PRVR2, and probe PRVP1; lane 1: result of iiPCR performed without DNA template (negative control); lanes 2 to 7: results of iiPCR performed with 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of in vitro transcriptional RNA of PRV respectively.
  • FIG. 1 shows the results of iiPCR test for sensitivity of primers PRVF3, PRVR2, and probe PRVP1
  • lane 1 result of iiPCR performed without DNA template (negative control)
  • lanes 2 to 7 results of iiPCR performed with 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of in vitro transcriptional RNA of PRV respectively.
  • 2F shows the results of iiPCR test for sensitivity of primers PRVF5, PRVR5, and probe PRVP2; lane 1: result of iiPCR performed without DNA template (negative control); lanes 2 to 7: results of iiPCR performed with 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of pUC57-PRV plasmid respectively.
  • FIG. 1 shows the results of iiPCR test for sensitivity of primers PRVF5, PRVR5, and probe PRVP2
  • lane 1 result of iiPCR performed without DNA template (negative control)
  • lanes 2 to 7 results of iiPCR performed with 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of pUC57-PRV plasmid respectively.
  • 2G shows the results of iiPCR test for sensitivity of primers PRVF5, PRVR5, and probe PRVP2; lane 1: result of iiPCR performed without DNA template (negative control); lanes 2 to 7: results of iiPCR performed with 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of in vitro transcriptional RNA of PRV respectively.
  • M represents molecular weight marker; arrows indicate the target PCR products; “+” indicates fluorescent signal was detected in the sample, and “ ⁇ ” indicates fluorescent signal was not detected in the sample.
  • FIG. 3A shows the results of conventional PCR test of infectious pancreatic necrosis virus (IPNV) with primers IPNVF1 and IPNVR1; lanes 1 to 5: results of conventional PCR performed with 10 5 , 10 4 , 10 3 , 10 2 , 10 1 copies of pTA-IPNV plasmid respectively; lane 6: results of conventional PCR performed without DNA template (negative control).
  • IPNV infectious pancreatic necrosis virus
  • FIG. 3B shows the results of RT-PCR (reverse transcription PCR) test of IPNV with primers IPNVF1 and IPNVR1; lanes 1 to 6: results of RT-PCR performed with 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 -fold diluted total RNA respectively; lane 7: results of RT-PCR performed without RNA sample (negative control).
  • FIG. 1 shows the results of RT-PCR (reverse transcription PCR) test of IPNV with primers IPNVF1 and IPNVR1; lanes 1 to 6: results of RT-PCR performed with 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 -fold diluted total RNA respectively; lane 7: results of RT-PCR performed without RNA sample (negative control).
  • 3C shows the results of iiPCR test of IPNV with different primers; lane 1: result of iiPCR performed with pTA-IPNV and primers IPNVF1 and IPNVR1 and probe IPNVP1; lane 2: result of iiPCR performed with primers IPNVF1 and IPNVR1 and probe IPNVP1 but without DNA template (negative controls); lane 3: result of iiPCR performed with pTA-IPNV and IPNVF1 and IPNVR2 and probe IPNVP1; lane 4: result of iiPCR performed with IPNVF1 and IPNVR2 and probe IPNVP1 but without DNA template (negative controls).
  • FIG. 1 result of iiPCR performed with pTA-IPNV and primers IPNVF1 and IPNVR1 and probe IPNVP1
  • lane 2 result of iiPCR performed with primers IPNVF1 and IPNVR1 and probe IPNVP1 but without DNA template (negative controls)
  • lane 3 result of iiPCR performed with pTA
  • 3D shows the results of iiPCR test for sensitivity of primers IPNVF1, IPNVR1, and probe IPNVP1 with pTA-IPNV plasmid; lanes 1 to 5: results of iiPCR performed with 10 5 , 10 4 , 10 3 , 10 2 , 10 1 copies of pTA-IPNV plasmid respectively; lane 6: result of iiPCR performed without DNA template (negative control).
  • 3E shows the results of iiPCR test for sensitivity of primers IPNVF1, IPNVR1, and probe IPNVP1 with in vitro transcriptional RNA of IPNV; lane 1: result of iiPCR performed without DNA template (negative control); lanes 2 to 7: results of iiPCR performed with 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of in vitro transcriptional RNA of IPNV respectively.
  • 3F shows the results of iiPCR test for sensitivity of primers IPNVF1, IPNVR1, and probe IPNVP1 with serially diluted RNA of IPNV; lanes 1 to 6: results of iiPCR performed with stock (10 0 ), 10 3 , 10 4 , 10 5 , 10 6 , 10 7 -fold diluted total RNA of IPNV respectively; lane 7: result of iiPCR performed without RNA template (negative control); lane 8: result of iiPCR performed with DNA template (positive control).
  • FIG. 3G shows the results of iiPCR test for specificity of primers IPNVF1, IPNVR1, and probe IPNVP1; lane 6: result of iiPCR performed without RNA template (negative control); lanes 1 to 5, and 7: results of iiPCR performed with DNA/RNA template of ISAV, SAV, NNV, PRV, salmon muscle tissue, and pTA-IPNV plasmid respectively.
  • FIG. 3H shows the results of real-time PCR test of infectious pancreatic necrosis virus (IPNV), pTA-IPNV plasmid, with primers IPNVF1, IPNVR1.
  • IPNV infectious pancreatic necrosis virus
  • M represents molecular weight marker
  • arrows indicate the target PCR products
  • “+” indicates fluorescent signal was detected in the sample
  • ⁇ ” indicates fluorescent signal was not detected in the sample.
  • FIG. 4A shows the results of iiPCR test of salmonid alphavirus (SAV) with different primers; lanes 1, 3, and 5: result of iiPCR performed without pTA-SAV but with primers SAVF1 and SAVR1, primers SAVF2 and SAVR2, and primers SAVF3 and SAVR3 (negative controls); lanes 2, 4, and 6: result of iiPCR performed with pTA-SAV and primers SAVF1 and SAVR1, primers SAVF2 and SAVR2, primers SAVF3 and SAVR3 respectively.
  • SAV salmonid alphavirus
  • FIG. 4B shows the results of iiPCR test for sensitivity of primers SAVF1 and SAVR1, and probe SAVP1 with pTA-SAV plasmid; lanes 1 to 5: results of iiPCR performed with 10 5 , 10 4 , 10 3 , 10 2 , 10 1 copies of pTA-SAV plasmid respectively; lane 6: result of iiPCR performed without DNA template (negative control).
  • FIG. 4B shows the results of iiPCR test for sensitivity of primers SAVF1 and SAVR1, and probe SAVP1 with pTA-SAV plasmid; lanes 1 to 5: results of iiPCR performed with 10 5 , 10 4 , 10 3 , 10 2 , 10 1 copies of pTA-SAV plasmid respectively; lane 6: result of iiPCR performed without DNA template (negative control).
  • 4C shows the results of iiPCR test for sensitivity of primers SAVF1 and SAVR1, and probe SAVP1 with in vitro transcriptional RNA of SAV; lane 1: result of iiPCR performed without RNA template (negative control); lanes 2 to 7: results of iiPCR performed with 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of in vitro transcriptional RNA of SAV respectively.
  • FIG. 4D shows the results of iiPCR test for sensitivity of primers SAVF1 and SAVR1, and probe SAVP1 with serially diluted RNA of SAV; lane 1: result of iiPCR performed with DNA template (positive control); lanes 2 to 6: results of iiPCR performed with 10 1 , 10 3 , 10 4 , 10 5 , 10 6 -fold diluted total RNA of SAV respectively; lane 7: result of iiPCR performed without RNA template (negative control).
  • FIG. 4E shows the results of real-time PCR test of SAV, pTA-SAV plasmid, with primers SAVF1 and SAVR1.
  • “M” represents molecular weight marker; arrows indicate the target PCR products; “+” indicates fluorescent signal was detected in the sample, and “ ⁇ ” indicates fluorescent signal was not detected in the sample.
  • FIG. 5A shows the results of conventional PCR test of infectious salmonanemia virus (ISAV) with primers ISAVF1 and ISAVR1; lanes 1 to 5: results of conventional PCR performed with 10 5 , 10 4 , 10 3 , 10 2 , 10 1 copies of pTA-ISAV plasmid respectively; lane 6: results of conventional PCR performed without DNA template (negative control).
  • ISAV infectious salmonanemia virus
  • 5B shows the results of iiPCR test of ISAV with different primers
  • lanes 1, 3, 5, and 7 results of iiPCR performed with pTA-ISAV plasmid and primers ISAVF1 and ISAVR1, primers ISAVF1 and ISAVR2, primers ISAVF2 and ISAVR2, primers ISAVF2 and ISAVR1 respectively
  • lanes 2, 4, 6, and 8 results of iiPCR performed without DNA but with primers ISAVF1 and ISAVR1, primers ISAVF1 and ISAVR2, primers ISAVF2 and ISAVR2, primers ISAVF2 and ISAVR1 respectively (negative controls).
  • 5C shows the results of iiPCR test for sensitivity of primers ISAVF1 and ISAVR1, and probe ISAVP2 with pTA-ISAV plasmid; lane 1: result of iiPCR performed without DNA template (negative control); lanes 2 to 7: results of iiPCR performed with 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies of pTA-ISAV plasmid respectively.
  • 5D shows the results of iiPCR test for sensitivity of primers ISAVF1 and ISAVR1, and probe ISAVP2 with serially diluted RNA of SAV; lane 1: result of iiPCR performed without RNA template (negative control); lanes 2 to 7: results of iiPCR performed with 10 7 , 10 6 , 10 5 , 10 4 , 10 3 , 10 2 -fold diluted total RNA of ISAV respectively.
  • FIG. 5E shows the results of iiPCR test for specificity of primers ISAVF1 and ISAVR1, and probe ISAVP2; lane 1: result of iiPCR performed without RNA template (negative control); lanes 2 to 7: results of iiPCR performed with DNA/RNA template of SAV, IPVN, NNV, PRV, salmon muscle tissue, and pTA-ISAV plasmid respectively.
  • FIG. 5F shows the results of real-time PCR test of ISAV, pTA-ISAV plasmid, with primers ISAVF1 and ISAVR1.
  • “M” represents molecular weight marker; arrows indicate the target PCR products; “+” indicates fluorescent signal was detected in the sample, and “ ⁇ ” indicates fluorescent signal was not detected in the sample.
  • the disclosure relates to a method for detecting a pathogen in coldwater fish.
  • the method is polymerase chain reaction (PCR).
  • the method is reverse-transcription polymerase chain reaction (RT-PCR).
  • RT-PCR reverse-transcription polymerase chain reaction
  • iiPCR insulated isothermal polymerase chain reaction
  • the method is real-time quantitative polymerase chain reaction (real-time PCR).
  • the disclosure relates to a method for detecting a pathogen in coldwater fish, comprising:
  • oligonucleotide primer pair defining the 5′ ends of two complementary strands of a double stranded target sequence on the one or more nucleotide sequences of the pathogen;
  • dATPs deoxyadenosine triphosphates
  • dCTPs deoxycytidine triphosphates
  • dGTPs deoxyguanosine triphosphates
  • dTTPs deoxythymidine triphosphates
  • iiPCR insulated isothermal polymerase chain reaction
  • the disclosure relates to a method for detecting a pathogen in coldwater fish, comprising:
  • oligonucleotide primer pair defining the 5′ ends of two complementary strands of a double stranded target sequence on the one or more nucleotide sequences of the pathogen;
  • an oligonucleotide probe having a sequence complementary to a segment of the double stranded target sequence, a fluorescer molecule attached to a first location on the oligonucleotide probe, and a quencher molecule attached to a second location on the oligonucleotide probe such that the quencher molecule substantially quenches the fluorescer molecule whenever the oligonucleotide probe is not hybridized to the segment of the double stranded target sequence and such that the fluorescer molecule is substantially unquenched whenever the oligonucleotide probe is hybridized to the segment of the double stranded target sequence;
  • dATPs deoxyadenosine triphosphates
  • dCTPs deoxycytidine triphosphates
  • dGTPs deoxyguanosine triphosphates
  • dTTPs deoxythymidine triphosphates
  • iiPCR insulated isothermal polymerase chain reaction
  • the disclosure relates to a pair of oligonucleotides for detecting pathogens in coldwater fish.
  • the disclosure relates to a pair of oligonucleotides and an oligonucleotide probe for detecting pathogens in coldwater fish.
  • a pair of oligonucleotides and/or an oligonucleotide probe disclosed herein may be used in variations on the basic PCR technique, such as but not limited to, reverse-transcription PCR (RT-PCR), insulated isothermal PCR (iiPCR), real-time quantitative PCR (real-time PCR), nested PCR, and thermal asymmetric interlaced PCR (TAIL-PCR).
  • RT-PCR reverse-transcription PCR
  • iiPCR insulated isothermal PCR
  • real-time quantitative PCR real-time quantitative PCR
  • nested PCR nested PCR
  • thermal asymmetric interlaced PCR asymmetric interlaced PCR
  • coldwater refers to water areas on the northern and southern hemisphere with water temperatures ranging from freezing during winter and up to 15-20° C. during summer.
  • Coldwater fish includes salmonids such as, but not limited to, Atlantic salmon, Coho salmon, Chinook salmon and Rainbow trout, furthermore marine species like halibut, cod and flounders.
  • the coldwater fish is salmon.
  • a pathogen in coldwater fish refers to viral, bacterial and parasitic pathogen found in coldwater fish.
  • pathogens in coldwater fish are such as but not limited to a) virus: IPNV (infectious pancreatic disease virus), SPDV (salmon pancreatic disease virus), ISAV (infectious salmon anemia virus), HSMIV (heart and skeletal muscle inflammation virus), IHNV (infectious hematopoietic necrosis virus), VHSV (viral hemorrhagic septicemia virus), VNNV (viral nervous necrosis virus);
  • bacteria BKD (bacterial kidney diseas) Vibrio anguillarum, Vibrio salmonicida, Aeromonas salmonicida, Myxosoma cerebralis, Flavobacterium columnare Yersinia ruckeri, Candidatus Branchiomonas cysticola ;
  • parasites AGD (amoebic gill disease) and sea lice
  • insulated isothermal polymerase chain reaction refers to a polymerase chain reaction in which spontaneous fluid convection in a tube is driven by temperature gradients that are formed simply by heating the vessel from the bottom at a fixed temperature. Consequently, reaction constituents are circulated through zones of temperature gradients, and the denaturation, annealing, and extension steps of PCR take place at the bottom, top, and middle zones of the tube, respectively.
  • iiPCR insulated isothermal polymerase chain reaction
  • the term “fluorescer molecule” refers to a substance or a portion thereof which is capable of exhibiting fluorescence in the detectable range.
  • the term “quencher molecule” refers to a substance or a portion thereof which is capable of quenching the fluorescence emitted by the fluorescer molecule when excited by a light source.
  • the terms “fluorescer molecule” and “quencher molecule” are the fluorescer molecule and the quencher molecule of the TaqManTM assay (Applied Biosystems Inc., CA, US).
  • Example of the fluorescer molecule includes, but not limited to, 3-( ⁇ -carboxypentyl)-3′-ethyl-5,5′-dimethyloxa-carbocyanine (CYA); 6-carboxyfluorescein (FAM); 5,6-carboxyrhodamine-110 (R110); 6-carboxyrhodamine-6G (R6G); N′,N′,N′,N′-tetramethyl-6-carboxyrhodamine (TAMRA); 6-carboxy-X-rhodamine (ROX); 2′,4′,5′, T, -tetrachloro-4-7-dichlorofluorescein (TET); 2′,7-dimethoxy-4′,5′-6 carboxyrhodamine (JOE); 6-carboxy-2′,4,4′,5′,7,7′-hexachlorofluorescein (HEX); ALEXA; Cy3 and Cy5.
  • CYA
  • Example of the quencher molecule includes, but not limited to, 4-(4′-dimethylamino-phenylazo)-benzoic acid (Dabcyl), Black Hole Quencher 1 (BHQ1), Black Hole Quencher 2 (BHQ2), Black Hole Quencher 3 (BHQ3), tetramethylrhodamine (TAMRA).
  • the fluorescer molecule is 6-carboxyfluorescein (6-FAM)
  • the quencher molecule is dihydrocyclopyrroloindole tripeptide minor groove binder (MGB).
  • the 16S ribosomal RNA gene of Candidatus Branchiomonas cysticola was inserted in pUC57 cloning vector (Thermo, Mass., US) to obtain pUC57-BC plasmid.
  • the 50 ⁇ l PCR mixture for conventional PCR contains diluted pUC57-BC plasmid (10 10 , 10 9 , 10 8 , 10 7 , 10 6 , 10 5 , 10 4 , 10 3 , 10 2 , 10 1 , 10 0 copies respectively), 0.01-2 ⁇ M forward primer BCF1 (SEQ ID NO: 1), 0.01-2 ⁇ M reverse primer BCR1 (SEQ ID NO: 2), 0.2 ⁇ M dNTP, and 1.25 U Prime Taq DNA polymerase.
  • the amplification was performed in a thermal cycler (such as, but not limited to, PC818, Astec Co. Ltd., Japan) and consisted of one initial cycle of denaturation for 3 minutes at 94° C.
  • FIG. 1A The results of the conventional PCR are presented in FIG. 1A .
  • the bands in lanes 1 to 9 show that the primers BCF1 and BCR1 of the invention have correctly amplified the 90-bp target sequence, whereas no target sequence has been amplified in the negative control (lane 12).
  • the results demonstrate that the primers can be used in conventional PCR amplification to detect the existence of Candidatus Branchiomonas cysticola.
  • the 50 ⁇ l PCR mixture containing pUC57-BC plasmid (10 0 , 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies respectively), 0.01-2 ⁇ M forward primer BCF1 (SEQ ID NO: 1), 0.01-2 ⁇ M reverse primer BCR1 (SEQ ID NO: 2), 0.01-2 ⁇ M probe BCP1 (5′ FAM-CAGGCTTTCCTCTCCCA-MGB 3′, SEQ ID NO: 3), 1 ⁇ qPCR buffer, and 1-5 units of Taq DNA polymerase, was added in a reaction tube and incubated in an iiPCR machine for a designated period of time (about 1 hour). The fluorescence of FAM in each sample was detected by the iiPCR machine. In addition, amplicons were analyzed subsequently on a 15% polyacrylamide gel in TAE buffer and visualized by ethidium bromide staining
  • FIG. 1B The results of the iiPCR are presented in FIG. 1B .
  • the bands in lanes 2 to 7 show that the primers and probe of the invention have correctly amplified the 90-bp target sequence (indicated by arrows), whereas no target sequence has been amplified in the negative control (lane 1).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in the negative control.
  • primer BCF1 SEQ ID NO: 1
  • primer BCR1 SEQ ID NO: 2
  • probe BCP1 SEQ ID NO: 3
  • primer BCF1 SEQ ID NO: 1
  • primer BCR1 SEQ ID NO: 2
  • probe BCP1 SEQ ID NO: 3
  • the 50 ⁇ l PCR mixture containing DNA extraction from salmon gill or DNA/RNA templates of different fish pathogens (SAV, IPNV, ISA, NNV, PRV, and pUC57-BC plasmid, respectively
  • 0.01-2 ⁇ M forward primer BCF1 SEQ ID NO: 1
  • 0.01-2 ⁇ M reverse primer BCR1 SEQ ID NO: 2
  • probe BCP1 5′ FAM-CAGGCTTTCCTCTCCCA-MGB 3′, SEQ ID NO: 3
  • 1 ⁇ qPCR buffer 10 units of Taq DNA polymerase
  • FIG. 1C The results of the iiPCR are presented in FIG. 1C .
  • the 90-bp target sequence (indicated by arrows) has been correctly amplified only in the sample containing Candidatus Branchiomonas cysticola DNA template (lane 8), whereas no target sequence has been amplified in samples containing DNA/RNA template of fish gill, SAV, IPNV, ISA, NNV, or PRV (lanes 1 to 7).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in lanes 1 to 7.
  • the 50 ⁇ l PCR mixture containing pUC57-BC plasmid (10 8 copies), 0.01-2 ⁇ M forward primer BCF2 (SEQ ID NO: 23) or BCF3 (SEQ ID NO: 25) or BCF4 (SEQ ID NO: 27), 0.01-2 ⁇ M reverse primer BCR2 (SEQ ID NO: 24) or BCR3 (SEQ ID NO: 26) or BCR4 (SEQ ID NO: 28), 0.01-2 ⁇ M probe BCP2 (5′ FAM-CGGCGTGCCTGAGAA-MGB 3′, SEQ ID NO: 29), 1 ⁇ qPCR buffer, and 5 units of Taq DNA polymerase, was added in a reaction tube and incubated in an iiPCR machine for a designated period of time (about 1 hour). The fluorescence of FAM in each sample was detected by the iiPCR machine. In addition, amplicons were analyzed subsequently on a 15% polyacrylamide gel in TAE buffer and visualized by ethidium bromide staining
  • FIG. 1D The results of the iiPCR are presented in FIG. 1D .
  • the bands in lanes 2, 4, and 6 show that the primers BCF2 (SEQ ID NO: 23) and BCR2 (SEQ ID NO: 24), BCF3 (SEQ ID NO: 25) and BCR3 (SEQ ID NO: 26), BCF4 (SEQ ID NO: 27) and BCR4 (SEQ ID NO: 28) have correctly amplified the 100-bp, 75-bp, and 100-bp target sequences (indicated by arrows) respectively, whereas no target sequence has been amplified in the negative controls (lanes 1, 3, and 5).
  • primer BCF3 SEQ ID NO: 25
  • primer BCR3 SEQ ID NO: 26
  • probe BCP2 SEQ ID NO: 29
  • the bands in lanes 3 to 8 show that the primers and probe of the invention have correctly amplified the 75-bp target sequence (indicated by arrows), whereas no target sequence has been amplified in the negative control and the sample with 10 0 copy of pUC57-BC plasmid (lanes 1 and 2).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in lanes 1 and 2.
  • Real-time PCR assay were carried out in a real time PCR machine (such as, but not limited to ABI StepOnePlusTM; Applied BioSystem, Life Technologies, CA, USA) using diluted pUC57-BC plasmid (10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies).
  • Real-time PCR assays were performed with 2 ⁇ l pUC57-BC plasmid, 0.01-2 ⁇ M forward primer BCF3 (SEQ ID NO: 25), 0.01-2 ⁇ M reverse primer BCR3 (SEQ ID NO: 26), and 0.01-2 ⁇ M probe BCP2 (5′ FAM-CGGCGTGCCTGAGAA-MGB 3′, SEQ ID NO: 29) in a total volume of 20 ⁇ l by using a commercial RT-PCR Kit (such as, but not limited to, OneStep PrimeScriptTM RT-PCR Kit; Takara Bio Inc., Japan).
  • the program included an incubation period at 42° C. 5 min, 94° C. for 10 sec, and 40 cycles of 94° C. for 10 sec and 60° C. for 30 min. Fluorescence measurements were recorded at the 60° C. step.
  • the standard curve for the serial dilutions (10-fold) of the pUC57-BC plasmid was calculated for the real-time PCR assays. At least 10 copies of pUC57-BC plasmid can be detected.
  • the R 2 value of the standard curve is 0.994, indicating the primers and the probe of the present invention can be used in real-time PCR to produce reliable outcomes.
  • the segment L1 of piscine reovirus (PRV, GenBank accession No. GU994013) was inserted in pUC57 cloning vector (Thermo) to obtain pUC57-PRV plasmid.
  • in vitro transcriptional RNA template of PRV was prepared by transcribing the DNA sequence of the PRV segment L1 with a commercial kit (such as, but not limited to, MAXlscript® Kit; Thermo Fisher Scientific, MA, USA).
  • the 50 ⁇ l PCR mixture for conventional PCR contains diluted pUC57-PRV plasmid (10 6 , 10 5 , 10 4 , 10 3 , 10 2 , 10 1 copies respectively), 0.01-2 ⁇ M forward primer PRVF1 (SEQ ID NO: 4), 0.01-2 ⁇ M reverse primer PRVR1 (SEQ ID NO: 5), 0.2 ⁇ M dNTP, and 1.25 U Prime Taq DNA polymerase.
  • the amplification was performed in a thermal cycler (such as, but not limited to, Astec Co. Ltd.) and consisted of one initial cycle of denaturation for 3 minutes at 94° C. and 35 cycles of 30 seconds at 94° C., 30 seconds at 60° C. and 30 seconds of extension at 72° C.
  • the amplicons were analyzed subsequently on a 15% polyacrylamide gel in TAE buffer and visualized by ethidium bromide staining
  • FIG. 2A The results of the conventional PCR are presented in FIG. 2A .
  • the bands in lanes 1 to 3 show that the primers PRVF1 and PRVR1 of the invention have correctly amplified the 86-bp target sequence, whereas no target sequence has been amplified in the negative control (lane 7).
  • the results demonstrate that the primers can be used in conventional PCR amplification to detect the existence of piscine reovirus (PRV).
  • PRV piscine reovirus
  • the 50 ⁇ l PCR mixture containing pUC57-PRV plasmid, 0.01-2 ⁇ M forward primer PRVF1 (SEQ ID NO: 4) or PRVF2 (SEQ ID NO: 30) or PRVF3 (SEQ ID NO: 32) or PRVF4 (SEQ ID NO: 33), 0.01-2 ⁇ M reverse primer PRVR1 (SEQ ID NO: 5) or PRVR2 (SEQ ID NO: 31) or PRVR4 (SEQ ID NO: 34), 0.01-2 ⁇ M probe PRVP1 (5′ FAM-CTCCAGGAGTCATTGTC-MGB 3′, SEQ ID NO: 6), 1 ⁇ qPCR buffer, and 5 units of Taq DNA polymerase, was added in a reaction tube and incubated in an iiPCR machine for a designated period of time (about 1 hour). The fluorescence of FAM in each sample was detected by the iiPCR machine. In addition, amplicons were analyzed subsequently on a 15% polyacrylamide gel in TAE buffer and visualized by ethi
  • FIG. 2B and FIG. 2C The results of the iiPCR are presented in FIG. 2B and FIG. 2C .
  • the bands in lanes 1 and 3 show that the primers PRVF1 (SEQ ID NO: 4) and PRVR1 (SEQ ID NO: 5) have correctly amplified the 86-bp target sequence (indicated by arrows), whereas no target sequence has been amplified in the negative controls (lanes 2 and 4).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in the negative controls.
  • the bands in lanes 2, 4, 6, 8, 10, and 12 show that the primers PRVF2 (SEQ ID NO: 30) and PRVR2 (SEQ ID NO: 31), PRVF3 (SEQ ID NO: 32) and PRVR2 (SEQ ID NO: 31), PRVF4 (SEQ ID NO: 33) and PRVR4 (SEQ ID NO: 34) have correctly amplified the 89-bp, 83-bp, and 100-bp target sequences (indicated by arrows) respectively, whereas no target sequence has been amplified in the negative controls (lanes 1, 3, 5, 7, 9, and 11).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in the negative controls.
  • sensitivity evaluation of primers PRVF2 (SEQ ID NO: 30) and PRVR2 (SEQ ID NO: 31), and PRVF3 (SEQ ID NO: 32) and PRVR2 (SEQ ID NO: 31), and probe PRVP1 (SEQ ID NO: 6) was conducted by repeating the iiPCR analysis mentioned above with different copies (10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies respectively) of in vitro transcriptional RNA template of PRV.
  • the result of the sensitivity test is shown in FIG. 2D (for primers PRVF2, PRVR2 and probe PRVP1) and FIG. 2E and Table 3 (for primers PRVF3, PRVR2 and probe PRVP1), respectively.
  • the bands in lanes 4 to 7 show that the primers PRVF2 and PRVR2 and probe PRVP1 have correctly amplified the 89-bp target sequence (indicated by arrows), whereas no target sequence has been amplified in the negative control and the sample with 10 1 and 10 2 copies of in vitro transcriptional RNA (lanes 1, 2, and 3).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in lanes 1, 2, and 3.
  • the bands in lanes 3 to 7 show that the primers PRVF3, PRVR2 and probe PRVP1 have correctly amplified the 83-bp target sequence (indicated by arrows), whereas no target sequence has been amplified in the negative control and the sample with 10 1 copy of in vitro transcriptional RNA (lanes 1 and 2).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in lanes 1 and 2.
  • the statistical data of eight (8) repeats of the sensitivity test is shown in Table 3.
  • the 50 ⁇ l PCR mixture containing pUC57-PRV plasmid (10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies respectively) or in vitro transcriptional RNA template of PRV (10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies respectively), 0.01-2 ⁇ M forward primer PRVF5 (SEQ ID NO: 35), 0.01-2 ⁇ M reverse primer PRVR5 (SEQ ID NO: 36), 0.01-2 ⁇ M probe PRVP2 (5′ FAM-CAATGGGATGCTAACACTC-MGB 3′, SEQ ID NO: 37), 1 ⁇ qPCR buffer, and 5 units of Taq DNA polymerase, was added in a reaction tube and incubated in an iiPCR machine for a designated period of time (about 1 hour).
  • the bands in lanes 3 to 7 show that the primers of the invention have correctly amplified the 72-bp target sequence (indicated by arrows), whereas no target sequence has been amplified in the negative control and the sample with 10 1 copy of pUC57-PRV plasmid (lanes 1 and 2 in FIG. 2F ) or in vitro transcriptional RNA template of PRV (lanes 1 and 2 in FIG. 2G ).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in lanes 1 and 2 in FIG. 2F or FIG. 2G .
  • the statistical data of four (4) repeats of the sensitivity test with in vitro transcriptional RNA template of PRV is shown in Table 4.
  • IPNV Infectious Pancreatic Necrosis Virus
  • IPNV infectious pancreatic necrosis virus
  • IPNV In vitro transcriptional RNA template of IPNV was prepared by transcribing the DNA sequence of the IPNV segment A with a commercial kit (such as, but not limited to, MAXlscript® Kit; Thermo Fisher Scientific, MA, USA).
  • a commercial kit such as, but not limited to, MAXlscript® Kit; Thermo Fisher Scientific, MA, USA.
  • RNA extraction from tissues was performed by using a commercial kit (such as, but not limited to, FavorPrepTM Viral Nucleic Acid Extraction kit; Favorgen Biotech Corp., Taiwan). The purity of the total RNA was evaluated by measuring the absorbance ration at 260/280 nm.
  • the 50 ⁇ l PCR mixture for conventional PCR contains diluted pTA-IPNV plasmid (10 5 , 10 4 , 10 3 , 10 2 , 10 1 copies respectively), 0.01-2 ⁇ M forward primer IPNVF1 (SEQ ID NO: 7), 0.01-2 ⁇ M reverse primer IPNVR1 (SEQ ID NO: 8), 0.2 ⁇ M dNTP, and 1.25 U Prime Taq DNA polymerase.
  • the amplification was performed in a thermal cycler (such as, but not limited to, Astec Co. Ltd.) and consisted of one initial cycle of denaturation for 3 minutes at 94° C. and 35 cycles of 30 seconds at 94° C., 30 seconds at 60° C. and 30 seconds of extension at 72° C.
  • the amplicons were analyzed subsequently on a 15% polyacrylamide gel in TAE buffer and visualized by ethidium bromide staining.
  • FIG. 3A The results of the conventional PCR are presented in FIG. 3A .
  • the bands in lanes 1 to 4 show that the primers and probe of the invention have correctly amplified the 83-bp target sequence, whereas no target sequence has been amplified in the negative control (lane 6).
  • the results demonstrate that the primers can be used in conventional PCR amplification to detect the existence of infectious pancreatic necrosis virus (IPNV).
  • IPNV infectious pancreatic necrosis virus
  • RT-PCR was performed by using a commercial kit (such as, but not limited to, One step RT-PCR kit; LTK Biolab, Taiwan) with the total RNA extraction from fish suffering from infectious pancreatic necrosis virus (IPNV), 0.01-2 ⁇ M forward primer IPNVF1 (SEQ ID NO: 7), and 0.01-2 ⁇ M reverse primer IPNVR1 (SEQ ID NO: 8).
  • IPNV infectious pancreatic necrosis virus
  • the reverse transcription reaction was carried out at 42° C. for 30 min, followed by a PCR program of 10 minutes at 94° C. and 35 cycles of 30 seconds at 94° C., 30 seconds at 60° C. and 30 seconds of extension at 72° C.
  • the amplicons were analyzed subsequently on a 15% polyacrylamide gel in TAE buffer and visualized by ethidium bromide staining
  • FIG. 3B The results of the RT-PCR are presented in FIG. 3B .
  • the bands in lanes 1 to 3 show that the primers of the invention have correctly amplified the 83-bp target sequence, whereas no target sequence has been amplified in the negative control (lane 7).
  • the results demonstrate that the primers can also be used in RT-PCR amplification to detect the existence of infectious pancreatic necrosis virus (IPNV).
  • IPNV infectious pancreatic necrosis virus
  • the 50 ⁇ l PCR mixture containing pTA-IPNV plasmid, 0.01-2 ⁇ M forward primer IPNVF1 (SEQ ID NO: 7), 0.01-2 ⁇ M reverse primer IPNVR1 (SEQ ID NO: 8) or IPNVR2 (SEQ ID NO: 9), 0.01-2 ⁇ M probe IPNVP1 (5′ FAM-ACGCTCAACGCTGCCA-MGB 3′, SEQ ID NO: 10), 1 ⁇ qPCR buffer, and 5 units of Taq DNA polymerase, was added in a reaction tube and incubated in an iiPCR machine for a designated period of time (about 1 hour). The fluorescence of FAM in each sample was detected by the iiPCR machine. In addition, amplicons were analyzed subsequently on a 15% polyacrylamide gel in TAE buffer and visualized by ethidium bromide staining
  • FIG. 3C The results of the iiPCR are presented in FIG. 3C .
  • the bands in lanes 1 and 3 show that the primers and probe of the invention have correctly amplified the 83-bp target sequence (primers IPNVF1 and IPNVR1) and 88-bp target sequence (primers IPNVF1 and IPNVR2) respectively, whereas no target sequence has been amplified in the negative controls (lanes 1 and 3).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in the negative controls.
  • primer IPNVF1 SEQ ID NO: 7
  • primer IPNVR1 SEQ ID NO: 8
  • probe IPNVP1 SEQ ID NO: 10
  • pTA-IPNV DNA plasmid 10 1 , 10 2 , 10 3 , 10 4 , 10 5 copies respectively
  • in vitro transcriptional RNA template of IPNV 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies respectively
  • total RNA extraction from fish suffering from IPNV original stock and 10 ⁇ 3 , 10 ⁇ 4 , 10 ⁇ 5 , 10 ⁇ 6 , 10 ⁇ 7 dilution, respectively.
  • 50 U MMLV RTase and 4 U RNase inhibitor were also added in the reactions. The results of the sensitivity tests are shown in FIGS. 3D , 3 E, 3 F.
  • the bands in lanes 1 to 5 show that the primers of the invention have correctly amplified the 83-bp target sequence (indicated by arrows), whereas no target sequence has been amplified in the negative control (lane 6).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in lane 6.
  • the bands in lanes 4 to 7 show that the primers of the invention have correctly amplified the 83-bp target sequence (indicated by arrows), whereas no target sequence has been amplified in the negative control and the sample with 10 1 and 10 2 copies of in vitro transcriptional RNA template of IPNV (lanes 1, 2 and 3).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in lanes 1, 2, and 3.
  • the bands in lanes 1, 2, 3, and 8 show that the primers of the invention have correctly amplified the 83-bp target sequence, whereas no target sequence has been amplified in the 10 ⁇ 5 , 10 ⁇ 6 , 10 ⁇ 7 diluted RNA samples and the negative control (lanes 4, 5, 6, and 7).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in the negative controls and the 10 ⁇ 5 , 10 ⁇ 6 , 10 ⁇ 7 diluted RNA samples.
  • the statistical data of five (5) repeats of the sensitivity test with RNA samples of PRV is shown in Table 5.
  • primer IPNVF1 SEQ ID NO: 7
  • primer IPNVR1 SEQ ID NO: 8
  • probe IPNVP1 SEQ ID NO: 10.
  • FIG. 3G The results of the iiPCR are presented in FIG. 3G .
  • the 83-bp target sequence (indicated by arrows) has been correctly amplified only in the sample containing IPNV RNA template (lane 7), whereas no target sequence has been amplified in samples containing DNA/RNA templates of ISAV, SAV, NNV, PRV, DNA extraction of Salmon muscle tissue, and negative control (lanes 1 to 6).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in lanes 1 to 6.
  • Real-time PCR assay were carried out in a real time PCR machine (such as, but not limited to, an ABI StepOnePlusTM real time PCR machine; Applied BioSystem, Life Technologies, CA, USA) using diluted pTA-IPNV plasmid (10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies).
  • a real time PCR machine such as, but not limited to, an ABI StepOnePlusTM real time PCR machine; Applied BioSystem, Life Technologies, CA, USA
  • Real-time PCR assays were performed with 2 ⁇ l pTA-IPNV plasmid, 0.01-2 ⁇ M forward primer IPNVF1 (SEQ ID NO: 7), 0.01-2 ⁇ M reverse primer IPNVR1 (SEQ ID NO: 8), and 0.01-2 ⁇ M probe IPNVP1 (5′ FAM-ACGCTCAACGCTGCCA-MGB 3′, SEQ ID NO: 10) in a total volume of 20 ul by using a commercial kit (such as, but not limited to, OneStep PrimeScriptTM RT-PCR Kit; Takara Bio Inc., Japan).
  • the program included an incubation period at 42° C. 5 min, 94° C. for 10 sec, and 40 cycles of 94° C. for 10 sec and 60° C. for 30 min. Fluorescence measurements were recorded at the 60° C. step.
  • the standard curve for the serial dilutions (10-fold) of the pTA-IPNV plasmid was calculated for the real-time PCR assays. At least 10 copies of pTA-IPNV plasmid can be detected.
  • the R 2 value of the standard curve is 0.99795, indicating the primers and the probe of the present invention can be used in real-time PCR to produce reliable outcomes.
  • a 984-bp partial sequence of salmonid alphavirus (SAV, GenBank accession No. KC122926, from nt 33 to 1016) was inserted in T&ATM cloning vector (Yeastern biotech) to obtain pTA-SAV plasmid.
  • RNA template of SAV was prepared by transcribing the DNA sequence of the 984-bp partial sequence of SAV with a commercial kit (such as, but not limited to, MAXIscript® Kit; Thermo Fisher Scientific, MA, USA).
  • RNA extraction from tissues was performed by using a commercial kit (such as, but not limited to, FavorPrepTM Viral Nucleic Acid Extraction kit; Favorgen Biotech Corp., Taiwan). The purity of the total RNA was evaluated by measuring the absorbance ration at 260/280 nm, and RNA quality was checked on an agarose (1%) gel in TAE buffer and visualized by ethidium bromide staining.
  • the 50 ⁇ l PCR mixture containing pTA-SAV plasmid, 0.01-2 ⁇ M forward primer SAVF1, SAVF2, or SAVF3 (SEQ ID NOs: 11, 12, or 13 respectively), 0.01-2 ⁇ M reverse primer SAVR1, SAVR2, or SAVR3 (SEQ ID NOs: 14, 15, or 16 respectively), 0.01-2 ⁇ M probe SAVP1 (5′ FAM-CGTGAGTTGTAAAGTAAAG-MGB 3′, SEQ ID NO: 17), 1 ⁇ qPCR buffer, and 5 units of Taq DNA polymerase, was added in a reaction tube and incubated in an iiPCR machine for a designated period of time (about 1 hour). The fluorescence of FAM in each sample was detected by the iiPCR machine. In addition, amplicons were analyzed subsequently on a 15% polyacrylamide gel in TAE buffer and visualized by ethidium bromide staining
  • FIG. 4A The results of the iiPCR are presented in FIG. 4A .
  • the bands in lanes 2, 4, and 6 show that the primers and probe of the invention have correctly amplified the 70-bp target sequence (primers SAVF1 and SAVR1), 85-bp target sequence (primers SAVF2 and SAVR2), and 70-bp target sequence (primers SAVF3 and SAVR3) respectively (indicated by arrows), whereas no target sequence has been amplified in the negative controls (lanes 1, 3, and 5).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in the negative controls.
  • primer SAVF1 SEQ ID NO: 11
  • primer SAVR1 SEQ ID NO: 14
  • probe SAVP1 SEQ ID NO: 17
  • pTA-SAV DNA plasmid 10 1 , 10 2 , 10 3 , 10 4 , 10 5 copies respectively
  • in vitro transcriptional RNA template of SAV 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies respectively
  • total RNA extraction from fish suffering from IPNV (original stock and 10 ⁇ 1 , 10 ⁇ 3 , 10 ⁇ 4 , 10 ⁇ 5 , 10 ⁇ 6 dilution, respectively.
  • 50 U MMLV RTase and 4 U RNase inhibitor were also added in the reactions. The results of the sensitivity tests are shown in FIGS. 4B , 4 C, and 4 D.
  • the bands in lanes 1 to 4 show that the primers of the invention have correctly amplified the 70-bp target sequence (indicated by arrows), whereas no target sequence has been amplified in the sample with 10 1 copies of pTA-SAV DNA plasmid and the negative control (lanes 5 and 6).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in lanes 5 and 6.
  • the bands in lanes 3 to 7 show that the primers of the invention have correctly amplified the 70-bp target sequence (indicated by arrows), whereas no target sequence has been amplified in the negative control and the sample with 10 1 copies of in vitro transcriptional RNA template of SAV (lanes 1 and 2).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in lanes 1 and 2.
  • the bands in lanes 1 to 6 show that the primers of the invention have correctly amplified the 70-bp target sequence from the extracted RNA, whereas no target sequence has been amplified in the negative controls (lane 7).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in the negative controls.
  • the statistical data of five (5) repeats of the sensitivity test with RNA samples of SAV is shown in Table 6.
  • Real-time PCR assay was carried out in an ABI StepOnePlusTM real time PCR machine (Applied BioSystem) using diluted pTA-SAV plasmid (10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies).
  • Real-time PCR assays were performed with 2 ⁇ l pTA-SAV plasmid, 0.01-2 ⁇ M forward primer SAVF1 (SEQ ID NO: 11), 0.01-2 ⁇ M reverse primer SAVR1 (SEQ ID NO: 14), and 0.01-2 ⁇ M probe SAVP1 (5′ FAM-CGTGAGTTGTAAAGTAAAG-MGB 3′, SEQ ID NO: 17) in a total volume of 20 ul by using a commercial kit (such as, but not limited to, OneStep PrimeScriptTM RT-PCR Kit; Takara Bio Inc., Japan).
  • the program included an incubation period at 42° C. 5 min, 94° C. for 10 sec, and 40 cycles of 94° C. for 10 sec and 60° C. for 30 min. Fluorescence measurements were recorded at the 60° C. step.
  • the standard curve for the serial dilutions (10-fold) of the pTA-SAV plasmid was calculated for the real-time PCR assays. At least 10 copies of pTA-SAV plasmid can be detected.
  • the R 2 value of the standard curve is 0.99046, indicating the primers and the probe of the present invention can be used in real-time PCR to produce reliable outcomes.
  • SAV salmonid alphavirus
  • a non-structural protein and matrix protein sequence of infectious salmon anemia virus (ISAV, GenBank accession No. DQ785286) was inserted in T&ATM cloning vector (Yeastern biotech) to obtain pTA-ISAV plasmid.
  • RNA extraction from tissues was performed by using a commercial kit (such as, but not limited to, FavorPrepTM Viral Nucleic Acid Extraction kit; Favorgen Biotech Corp., Taiwan). The purity of the total RNA was evaluated by measuring the absorbance ration at 260/280 nm, and RNA quality was checked on an agarose (1%) gel in TAE buffer and visualized by ethidium bromide staining
  • the 50 ⁇ l PCR mixture for conventional PCR contains diluted pTA-ISAV plasmid (10 5 , 10 4 , 10 3 , 10 2 , 10 1 copies respectively), 0.01-2 ⁇ M forward primer ISAVF1 (SEQ ID NO: 18), 0.01-2 ⁇ M reverse primer ISAVR1 (SEQ ID NO: 20), 0.2 ⁇ M dNTP, and 1.25 U Prime Taq DNA polymerase.
  • the amplification was performed in a thermal cycler (such as, but not limited to, Astec Co. Ltd.) and consisted of one initial cycle of denaturation for 3 minutes at 94° C. and 35 cycles of 30 seconds at 94° C., 30 seconds at 60° C. and 30 seconds of extension at 72° C.
  • the amplicons were analyzed subsequently on a 15% polyacrylamide gel in TAE buffer and visualized by ethidium bromide staining
  • FIG. 5A The results of the conventional PCR are presented in FIG. 5A .
  • the bands in lanes 1 to 3 show that the primers of the invention have correctly amplified the 92-bp target sequence, whereas no target sequence has been amplified in the negative control (lane 6).
  • the results demonstrate that the primers and the probe can be used in conventional PCR amplification to detect the existence of infectious salmon anemia virus (ISAV).
  • ISAV infectious salmon anemia virus
  • the 50 ⁇ l PCR mixture containing pTA-ISAV plasmid, 0.01-2 ⁇ M forward primer ISAVF1 or ISAVF2 (SEQ ID NOs: 18 or 19 respectively), 0.01-2 ⁇ M reverse primer ISAVR1 or ISAVR2 (SEQ ID NOs: 20 or 21 respectively), 0.01-2 ⁇ M probe ISAVP1 (5′ FAM-CGACGATGACTCTCTACTGTGT-MGB 3′, SEQ ID NO: 22) or ISAVP2 (5′ FAM-CGATGACTCTCTACTGTGTGA-MGB 3′, SEQ ID NO: 38), 1 ⁇ qPCR buffer, and 5 units of Taq DNA polymerase, was added in a reaction tube and incubated in an iiPCR machine for a designated period of time (about 1 hour).
  • the bands in lanes 1, 3, 5, and 7 show that the primers and probe ISAVP1 (SEQ ID NO: 22) of the invention have correctly amplified the 92-bp target sequence (primers ISAVF1 and ISAVR1), 93-bp target sequence (primers ISAVF1 and ISAVR2), 128-bp target sequence (primers ISAVF2 and ISAVR2), and 127-bp target sequence (primers ISAVF2 and ISAVR1) respectively, whereas no target sequence has been amplified in the negative controls (lanes 1, 3, 5, and 7).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in the negative controls.
  • the bands in lanes 5, 6, and 7 show that the primers ISAVF1 (SEQ ID NO: 18) and ISAVR1 (SEQ ID NO: 20) and probe ISAVP2 (5′ FAM-CGATGACTCTCTACTGTGTGA-MGB 3′, SEQ ID NO: 38) of the invention have correctly amplified the 92-bp target sequence in samples with 10 4 , 10 5 , 10 6 copies of pTA-ISAV plasmid, whereas no target sequence has been amplified in the negative controls and in samples with 10 1 , 10 2 , 10 3 copies of pTA-ISAV plasmid (lanes 1 to 4).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in lanes 1 to 4.
  • Sensitivity evaluation of primers ISAVF1 (SEQ ID NO: 18) and ISAVR1 (SEQ ID NO: 20) and probe ISAVP2 (5′ FAM-CGATGACTCTCTACTGTGTGA-MGB 3′, SEQ ID NO: 38) was also conducted by iiPCR analysis with total RNA extraction from fish suffering from ISAV (10 ⁇ 2 , 10 ⁇ 3 , 10 ⁇ 4 , 10 ⁇ 5 , 10 ⁇ 6 , 10 ⁇ 7 dilution, respectively).
  • the results of the iiPCR are presented in Table 7 and FIG. 5D .
  • the bands in lanes 4 to 7 show that the primers and probe of the invention have correctly amplified the 92-bp target sequence, whereas no target sequence has been amplified in the negative control and the 10 ⁇ 6 , 10 ⁇ 7 diluted RNA samples (lanes 1 to 3).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in the negative controls and the 10 ⁇ 6 , 10 ⁇ 7 diluted RNA samples.
  • primer ISAVF1 SEQ ID NO: 18
  • ISAVR1 SEQ ID NO: 20
  • probe ISAVP2 SEQ ID NO: 38
  • FIG. 5E The results of the iiPCR are presented in FIG. 5E .
  • the 92-bp target sequence (indicated by arrows) has been correctly amplified only in the sample containing ISAV RNA template (lane 7), whereas no target sequence has been amplified in negative control, samples containing DNA/RNA templates of SAV, IPNV, NNV, PRV, and DNA extraction from salmon muscle tissue (lanes 1 to 6).
  • significant probe hydrolysis was detected in the same mixtures by the iiPCR machine, whereas no fluorescent signal was detected in lanes 1 to 6.
  • Real-time PCR assay were carried out in an ABI StepOnePlusTM real time PCR machine (Applied BioSystem, Life Technologies, CA, USA) using diluted pTA-ISAV plasmid (10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 copies).
  • Real-time PCR assays were performed with 2 ⁇ l pTA-ISAV plasmid, 0.01-2 ⁇ M forward primer ISAVF1 (SEQ ID NO: 18), 0.01-2 ⁇ M reverse primer ISAVR1 (SEQ ID NO: 20), and 0.01-2 ⁇ M probe ISAVP2 (5′ FAM-CGATGACTCTCTACTGTGTGA-MGB 3′, SEQ ID NO: 38) in a total volume of 20 ul by using a commercial kit (such as, but not limited to, OneStep PrimeScriptTM RT-PCR Kit; Takara Bio Inc., Japan).
  • the program included an incubation period at 42° C. 5 min, 94° C. for 10 sec, and 40 cycles of 94° C. for 10 sec and 60° C. for 30 min. Fluorescence measurements were recorded at the 60° C. step.
  • the standard curve for the serial dilutions (10-fold) of the pTA-IPNV plasmid was calculated for the real-time PCR assays. At least 100 copies of pTA-ISAV plasmid can be detected.
  • the R 2 value of the standard curve is 0.992, indicating the primers and the probe of the present invention can be used in real-time PCR to produce reliable outcomes.
  • the results demonstrate that the primers and the probe can be used in iiPCR amplification to detect the existence of infectious salmon anemia virus (ISAV) with good sensitivity and specificity.
  • infectious salmon anemia virus ISAV

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US14/689,749 2014-04-18 2015-04-17 Methods for detecting pathogen in coldwater fish Abandoned US20150299813A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/689,749 US20150299813A1 (en) 2014-04-18 2015-04-17 Methods for detecting pathogen in coldwater fish

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461981311P 2014-04-18 2014-04-18
US14/689,749 US20150299813A1 (en) 2014-04-18 2015-04-17 Methods for detecting pathogen in coldwater fish

Publications (1)

Publication Number Publication Date
US20150299813A1 true US20150299813A1 (en) 2015-10-22

Family

ID=52946409

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/689,749 Abandoned US20150299813A1 (en) 2014-04-18 2015-04-17 Methods for detecting pathogen in coldwater fish

Country Status (7)

Country Link
US (1) US20150299813A1 (de)
EP (2) EP2933341B1 (de)
CN (2) CN105018593B (de)
CA (1) CA2887840C (de)
CL (1) CL2015000980A1 (de)
NO (1) NO3061893T3 (de)
TW (5) TWI542698B (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113637797A (zh) * 2021-07-13 2021-11-12 中山大学 用于检测鱼类神经坏死病毒的微滴式数字pcr方法及相应的试剂盒
EP3862443A4 (de) * 2018-10-05 2022-10-12 Schweitzer Biotech Company Ltd. Verfahren zum nachweis von fischpathogenen

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107099608A (zh) * 2017-06-13 2017-08-29 中国农业科学院兰州兽医研究所 一种检测山羊支原体山羊肺炎亚种的iiPCR试剂盒
NO344938B1 (en) * 2018-12-13 2020-07-20 Patogen As Pancreas Disease Virus Markers
CN111705163A (zh) * 2020-05-28 2020-09-25 中山大学达安基因股份有限公司 基于热对流pcr的新型冠状病毒快速检测试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
CA2219891C (en) 1995-05-05 2002-01-29 The Perkin-Elmer Corporation Methods and reagents for combined pcr amplification and hybridization probing assay
US8187813B2 (en) 2008-01-24 2012-05-29 Medigen Biotechnology Corp. Methods and apparatuses for convective polymerase chain reaction (PCR)
JP2012529892A (ja) * 2009-06-19 2012-11-29 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション ウイルス・アッセイ
EP2482825B1 (de) * 2009-10-02 2016-11-23 The Trustees of Columbia University in the City of New York Diagnostische fisch-reoviren-zusammensetzungen
CN101906486B (zh) * 2010-08-03 2012-10-17 中国水产科学研究院黄海水产研究所 检测多种鱼类病原的基因芯片及其检测方法
US9266110B2 (en) 2010-10-14 2016-02-23 Genereach Biotechnology Corp. Reaction tube for performing isothermal polymerase chain reaction therein
TW201215675A (en) 2010-10-14 2012-04-16 Genereach Biotechnology Corp A container for nucleic acid amplification reaction
TW201239088A (en) 2011-03-22 2012-10-01 Genereach Biotechnology Corp Convective polymerase chain reaction device
CN103687960A (zh) 2011-07-21 2014-03-26 瑞基海洋生物科技股份有限公司 反转录聚合酶链式反应的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cao et al., Use of a DNA Microarray for Detection and Identification of Bacterial Pathogens Associated with Fishery Products, 2011, Applied and Environmental Microbiology, Vol. 77, No. 23, Pages 8219-8225. *
GenBank Accession# JN968376, Candidatus Branchiomonas cysticola strain A1-483-L1 16S ribosomal RNA gene, complete sequence, published 4/24/2012. *
Mitchell et al., Candidatus Branchiomonas cysticola’ is a common agent of epitheliocysts in seawater-farmed Atlanticsalmon Salmo salar in Norway and Ireland, 2013, Diseases of Aquatic Organisms, Vol. 103, pages 35-43. *
Toenshoff et al., A Novel Betaproteobacterial Agent of Gill Epitheliocystis in Seawater Farmed Atlantic Salmon (Salmo salar), 2012, PLoS ONE, Vol. 7, Issue 3, e32696. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3862443A4 (de) * 2018-10-05 2022-10-12 Schweitzer Biotech Company Ltd. Verfahren zum nachweis von fischpathogenen
CN113637797A (zh) * 2021-07-13 2021-11-12 中山大学 用于检测鱼类神经坏死病毒的微滴式数字pcr方法及相应的试剂盒

Also Published As

Publication number Publication date
TW201546289A (zh) 2015-12-16
TWI542698B (zh) 2016-07-21
CN105018593A (zh) 2015-11-04
CL2015000980A1 (es) 2016-07-01
EP2933341A2 (de) 2015-10-21
EP2933341A3 (de) 2015-12-09
TWI648405B (zh) 2019-01-21
EP3216875A2 (de) 2017-09-13
EP2933341B1 (de) 2017-10-04
TW201738384A (zh) 2017-11-01
CN109022617A (zh) 2018-12-18
TW201840981A (zh) 2018-11-16
TWI660045B (zh) 2019-05-21
TW201631160A (zh) 2016-09-01
TWI635181B (zh) 2018-09-11
CA2887840C (en) 2020-04-14
TW201840857A (zh) 2018-11-16
EP3216875A3 (de) 2017-12-13
TWI660176B (zh) 2019-05-21
CA2887840A1 (en) 2015-10-18
NO3061893T3 (de) 2018-03-10
CN105018593B (zh) 2018-09-18

Similar Documents

Publication Publication Date Title
ES2494922T3 (es) Métodos para la amplificación, cuantificación e identificación de ácidos nucleicos
CA2887840C (en) Methods for detecting pathogen in coldwater fish
TWI784467B (zh) 用於偵測蝦白點症病毒(White spot syndrome virus, WSSV)之寡核苷酸對及探針
US20120190027A1 (en) Ligation-based method of normalized quantification of nucleic acids
TWI731425B (zh) 一種用於偵測非洲豬瘟病毒的寡核苷酸對及探針
JP6778374B2 (ja) 新規な陽性コントロール核酸を利用した、被検試料中の標的核酸の検出・定量法
US20120009575A1 (en) Inducible nucleic acid targets for detection of pathogens, methods and compositions thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: UPSTARTDNA CO. LTD., TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUO, TSUN-YUNG;HSIEH, WANG-JU;REEL/FRAME:036010/0542

Effective date: 20150701

AS Assignment

Owner name: SCHWEITZER BIOTECH COMPANY LTD., TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UPSTARTDNA CO. LTD.;REEL/FRAME:039276/0789

Effective date: 20160511

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION